Technology & Data Science for Enhanced Patient Care

JMSACL Logo

Learning Center

Access additional learning opportunities.

EUROPE 2015

Help Us Reach Our Educational Support Goal of $40,000
Educational Travel Grants supported in part by:
 

Video Viewing Request

You are requesting to view the following presentation:

Presented at 2015_EU

Clinical Utility of Reporting 3-Methoxytyramine as Part of a Plasma Metanephrines Profile
Sarah Pitkin
UCL Hospitals NHS Foundation Trust

The utility of reporting the dopamine metabolite 3-methoxytyramine (3-MT) in plasma free metanephrines profiles has been questioned due to analytical and clinical concerns. We developed and validated an LC-MS/MS assay for plasma free metanephrines, including 3-MT, and reviewed the analytical and clinical utility of reporting 3-MT over a 1 year period. Performance of the assay in an external quality assurance scheme was excellent. Clinically, 3-MT was found to be a valuable addition to the profile, providing a useful tumour marker for long term monitoring in one patient. Cabergoline therapy was found to decrease plasma 3-MT, whereas levodopa raised it.

Please Enter the email address used to register for the most recent conference and you will be emailed a link that will allow you to view the requested video.

Email: